UNIGE document Scientific Article
previous document  unige:79234  next document
add to browser collection

Pneumologie BPCO, asthme et fibrose pulmonaire

Published in Revue médicale suisse. 2015, vol. 11, no. 456-457, p. 129-134
Abstract In 2014, among new therapeutic approaches in pulmonary medicine, the role of inhaled corticosteroids has to be revaluated after the publication of the WISDOM and other studies. Their prescription should no longer be systematic even for "at risk" groups of patients, as defined by the GOLD consensus, but rather be considered on an individual basis. In the field of asthma, two major studies confirm the efficacy of mepoluzimab for the treatment of severe, eosinophilic asthma. Finally, for idiopathic pulmonary fibrosis, 2014 has taught us that treatment with N-acetylcystein is of no proven benefit, while pirfenidone and nintedanib are two new drugs that may attenuate the downhill course of the disease.
Keywords Adrenal Cortex Hormones/therapeutic useAntibodies, Monoclonal, Humanized/therapeutic useAsthma/drug therapyHumansPulmonary Disease, Chronic Obstructive/drug therapyPulmonary Fibrosis/drug therapySeverity of Illness Index
PMID: 25799669
Full text
Article (Published version) (514 Kb) - public document Free access
Research group Groupe Gasche-Soccal Paola (958)
(ISO format)
ROCHAT, Thierry, CHARBONNIER, Florian, PLOJOUX, Jérôme Pierre Olivier. Pneumologie BPCO, asthme et fibrose pulmonaire. In: Revue médicale suisse, 2015, vol. 11, n° 456-457, p. 129-134. https://archive-ouverte.unige.ch/unige:79234

416 hits



Deposited on : 2016-01-13

Export document
Format :
Citation style :